Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT Solution in Thailand

MELBOURNE, Australia–(BUSINESS WIRE)–Illumina, Inc., the global leader in DNA sequencing and array-based technologies and Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, today announced the launch of VeriSeq™ NIPT Solution v2 in Thailand, a CE-IVD, next-generation sequencing (NGS)-based approach to noninvasive prenatal... Read more

Danaher To Present At Jefferies Healthcare Conference

WASHINGTON, May 27, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced that Executive Vice President and Chief Financial Officer, Matt McGrew, will be presenting at the Jefferies Healthcare Conference on Wednesday, June 2, 2021 at 1:00 p.m. ET. The video will be simultaneously webcast on www.danaher.com.   ABOUT DANAHERDanaher is a global science and technology innovator... Read more

Bruker’s Molecular Phenomics Research Tools Enable New Insights into ‘Long COVID’ and Post-Acute Metabolic Abnormalities

Australian National Phenome Centre Integrates Quantitative NMR and MS Assay Platform for Risk Assessment and Longitudinal Monitoring of Post-Acute COVID-19 Syndrome (PACS) PERTH, Australia–(BUSINESS WIRE)– A clinical research collaboration on COVID-19 pheno-conversion and subsequent pheno-reversion has discovered transient and persistent systemic changes of the molecular signatures in patient blood samples three months after the acute... Read more

Danaher Announces Appointment of A. Shane Sanders to Danaher Board

Danaher Announces Appointment of A. Shane Sanders to Danaher Board WASHINGTON, May 13, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) announced today that it has appointed A. Shane Sanders to its Board of Directors and to its Audit Committee. This addition expands the size of Danaher’s Board from twelve to thirteen members. Mr. Sanders is currently Senior... Read more

Cancer Therapy Targets in Chromosome Instability

At the Cell Cycle and Genomic Stability Laboratory at Fundación Instituto Leloir (Argentina), Dr. Vanesa Gottifredi works under the hypothesis that DNA replication is a valid target for cancer therapy. DNA is essential for our development, survival and reproduction. However, DNA is constantly undergoing damage from a variety of factors, including byproducts of our metabolism,... Read more

International Organization of Vine and Wine (OIV) Officially Incorporates NMR Method in Compendium of International Methods of Analysis of Wines and Musts

ETTLINGEN, Germany–(BUSINESS WIRE)– Nuclear magnetic resonance (NMR) spectroscopy has been incorporated by the intergovernmental and International Organization of Vine and Wine (OIV) in its compendium of International Methods of Analysis of Wines and Musts, for the quantification of six key parameters in wine – glucose, malic acid, acetic acid, fumaric acid, shikimic acid and sorbic... Read more

PerkinElmer Announces Financial Results for the First Quarter of 2021

Revenue of $1.308 billion; 100% reported growth; 92% organic growth GAAP EPS from continuing operations of $3.37; Adjusted EPS of $3.72 Initiates Second Quarter and Raises Full-Year Revenue and Earnings Guidance WALTHAM, Mass.–(BUSINESS WIRE)–May 4, 2021– PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today reported financial results for... Read more

Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition

SAN DIEGO–(BUSINESS WIRE)–Illumina, Inc. (NASDAQ: ILMN) announced today that it has filed an action in the General Court of the European Union asking for annulment of the European Commission’s decision asserting jurisdiction to review Illumina’s acquisition of GRAIL. The Commission asserted jurisdiction to review the acquisition under Article 22 of the EU Merger Regulation on... Read more

Thermo Fisher Scientific Reports First Quarter 2021 Results

WALTHAM, Mass., April 29, 2021 /PRNewswire/ — Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended April 3, 2021. First Quarter 2021 Highlights First quarter revenue increased 59% to $9.91 billion. First quarter GAAP diluted earnings per share (EPS) increased 198% to $5.88.... Read more